Novo Nordisk's (NVO) semaglutide, sold under the brand name Ozempic, helped mitigate alcohol cravings in adults with alcohol use disorder in a clinical trial, researchers said in findings published Wednesday in the medical journal JAMA Psychiatry.
The researchers said results of the randomized trial offer preliminary prospective evidence supporting efficacy of low-dose semaglutide in reducing alcohol cravings, thus justifying further investigation in larger studies.
The trial that sought to evaluate the effects of once-weekly subcutaneous semaglutide on alcohol consumption and cravings involved nine weeks of outpatient treatment, with 48 participants receiving small doses ranging from 0.25 milligram to 1 mg per week.
Novo Nordisk did not immediately reply to MT Newswires' request for comment.
Price: 81.71, Change: -2.04, Percent Change: -2.43
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。